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Abstract
Background: The checkpointkinase 2 (CHK2) is part of the highly conserved ATM-CHK2 signaling pathway, which
is activated in response to DNA damage, in particular after double strand breaks which can be caused by
carcinogens like smoking. After induction of downstream targets, e.g. the tumor suppressor p53, its activation leads
to cell cycle arrest and apoptosis. Recently, the presence of CHK2 germ line mutations, primarily the 1100delC
variant, has been reported to be involved in carcinogenesis. The CHK2 1100delC variant results in a truncated
protein which is instable and inactive. Carriers of this variant have been shown to have an increased risk to
develop breast cancer and probably also other tumors. Our purpose was to investigate the role of CHK2 germ line
mutations in patients with squamous cell carcinoma of the head and neck (SCCHN).
Materials and Methods: We investigated 91 patients suffering from SCCHN including all tumor sites (oropharynx,
hypopharynx, larynx) for the presence of the germ line mutation 1100delC by direct sequence analysis. Patients
were characterized by their tumor localization, tumor stage, age, the presence of additional malignant tumors and
predisposing carcinogens (smoking, alcohol abuse).
Results: None of the patients, independently of the tumor site, age, the abuse of predisposing carcinogens, or the
presence of other kinds of tumors, carried the CHK2 1100delC variant.
Conclusions: The germ line CHK2 1100delC variant does not seem to have a major impact on the development of
SCCHN.
Background
Head and neck cancer is the fifth most common cancer
in the world [1]. The tumor suppressor p53 is strongly
involved in the carcinogenesis of these tumors and inac-
tivated either by mutations or human papilloma virus
(HPV) infection in most of the cases [2]. Furthermore,
squamous cell carcinomas of the head and neck
(SCCHN) are associated with smoking and alcohol con-
sumption as risk factors for their development [3].
These genotoxic substances lead to DNA damage; in
particular DNA double strand breaks that are removed
by different DNA repair mechanisms in healthy cells [4].
Two main checkpoint pathways are initiated in response
to DNA damage and lead to either apoptosis or cell
cycle arrest to allow chromatin repair: the ATR (ataxia
telangiectasia and Rad3 related)-CHK1 (checkpoint
kinase 1) -pathway and the ATM-CHK2-pathway. The
checkpoint kinase 2 (CHK2, CHEK2) acts as a signal
transducer within the highly conserved ataxia telangiec-
tasia-mutated (ATM) protein kinase - CHK2-signaling
pathway.
[5-10] Germ line mutations of p53 are normally the
hallmark of patients with Li-Fraumeni syndrome, who
t y p i c a l l yd e v e l o pt u m o r sa ta ne a r l ya g eo fl i f ea t
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line mutations in patients suffering from Li-Fraumeni
syndrome or Li-Fraumeni-like syndrome [11] without a
germ line p53 mutation. One of the most important
mutations was the 1100delC deletion. This variant leads
to a frame shift and encodes a premature stop codon
within the catalytic domain. The resulting truncated
protein is inactive and unstable [12]. The frequency of
the 1100delC variant differs within various populations
[5]. It was found in 0.9% of the Northrhine-Westphalia
population [13].
The CHK2 1100delC variant has been associated with
breast cancer in multiple-case families and has been
linked to an approximately 2-fold increased breast can-
cer risk. Thus, CHK2 is considered as a „low penetrance
gene” for breast cancer [14-18]. CHK2 mutations includ-
ing the 1100delC variant have also been associated to an
elevated risk for prostate [19-22] and bladder cancer
[23]. A correlation between CHK2 mutations and color-
ectal cancer [20,24,25], thyroid cancer and kidney cancer
is discussed [20]. CHK2 variants have also been found in
other tumors of the lung, larynx, pancreas, stomach as
well as melanoma [26], osteosarcoma [27], Non-Hodg-
kin lymphoma [28], myelodysplastic syndrome or acute
myeloid leukemia [29]. However, no definite relation to
increased cancer susceptibility was shown [20].
SCCHN are generally carcinogen-induced tumors that
show a high rate of p53 inactivation. Therefore, we
investigated the presence of the CHK2 1100delC germ
line mutation as a potential predisposition for the devel-
opment of SCCHN with special attention to multi-
tumor patients, and patients who are at low risk for
SCCHN with regard to age or carcinogen abuse.
Methods and Patients
Patients
The study consists of 91 consecutive patients with histo-
logically confirmed SCCHN, including all sites (57 oro-
pharynx, 12 hypopharynx, 22 larynx) and stages (T1-4,
N0-3,M 0/1) of disease. After obtaining informed consent,
blood samples were taken from each patient. Research
was carried out in compliance with the Helsinki
Declaration. This study was reviewed and approved by
the ethics committee of the University of Düsseldorf.
Sequencing of the CHK2 exon 10 including the 1100delC
variant
DNA was isolated from peripheral blood lymphocytes
(Genomic DNA purification kit, Genera Biosystems,
Minneapolis, USA). Exon 10 of the CHK2 gene was
amplified in a standard PCR reaction using Qiagen Mas-
termix (Qiagen, Hilden, Germany) and primers (5’-GCA
AAA TTA AAT GTC CTA ACT TGC-3’,5 ’-TCT GCC
CAG ACT TCA GGA AT-3’). PCR amplification was
performed as a “touch down PCR”.I tc o m p r i s e d3 5
cycles subdivided into 3 cycles of denaturing for 15 sec
at 94°C, annealing for 15 sec at 68°C, and extension for
45 sec at 72°C followed by 3 cycles of denaturing for 15
sec at 94°C, annealing for 15 sec at 63°C, and extension
for 45 sec at 72°C followed by 3 cycles of denaturing for
15 sec at 94°C, annealing for 15 sec at 58°C, and exten-
sion for 45 sec at 72°C. The PCR was preceded by 3
min at 94°C and followed by 7 min at 72°C. The ampli-
ficates were purified (Qiaquick, Qiagen), and mixed with
ABI PRISM BigDye Terminator sequencing kit (Applied
Biosystems, Weiterstadt, Germany) and primers (5’CCA
G A TT A AT G GC A GG T GT G - 3 ’ for sense direction
or 5’CCT ACC AGT CTG TGC AGC AA-3’for anti-
sense direction). After the sequencing reaction (25
cycles of 15 sec at 96°C and 4 min at 60°C), the pro-
ducts were gel-purified (DyeEx 2.0 Spin Kit, Qiagen)
and analyzed with an automated sequencer (ABI 310,
Applied Biosystems). A sample representing the wild
type sequence of CHK2 Exon 10 served as control. All
samples underwent confirmation by repeated analysis.
Results
The 91 investigated patients with histologically con-
firmed squamous cell carcinoma of the head and neck
(SCCHN) comprised 15 women and 76 men. Their age
ranged from 32 to 82 years with a mean of 56 years. A
relatively high proportion (12 patients) were aged under
40 years at the time of diagnosis and can thus be con-
sidered as young for the development of a SCCHN. The
majority (57) suffered from oropharyngeal carcinoma, 12
showed hypopharyngeal carcinoma, and 22 had laryn-
geal carcinoma (Table 1).
In 49 patients, cervical lymph node metastases were
found while 42 patients showed no metastases. Distant
metastases were determined in 3 patients. 21 patients
also suffered from other malignant or semi-malignant
tumors (Table 2). Some patients had tumors at multiple
sites. One patient had a history of an esophagus carci-
noma, a basal cell carcinoma, and a melanoma; another
one suffered from a prostate and a bladder carcinoma,
and one patient experienced a colon carcinoma and a
basal cell carcinoma.
Table 1 The table shows the number of patients with
different tumor subgroups and tumor stages.
Tumor Stage Oropharynx
n=5 7
Hypopharynx
n=1 2
Larynx
n=2 2
T1 16 1 10
T2 21 8 6
T3 15 1 3
T4 5 2 3
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portion of 75% (12 out of 16) of patients showing an
oropharyngeal cancer.
14 of those also were no habitual drinkers. Altogether,
23 patients reported moderate to seldom alcohol con-
sumption (less than once a week). The remaining
patients were mostly heavy smokers and drinkers.
Sequence analysis of exon 10 of the CHK2 gene was
performed for all patients. However, none of the
patients showed the presence of the 1100delC variant.
Discussion
None of the investigated 91 patients with SCCHN car-
ried the CHK2 1100delC variant. The incidence of
1100delC in the population of the state Northrhine-
Westphalia in Germany is reported to be 0.9%. Because
our investigation took place exactly in this region, we
accepted the published data as a control group for our
patients [13]. Hence, we did not determine any signifi-
cant difference in the incidence of the CHK2 1100delC
variant between the tumor group (0%) and the control
group (0.9%). Compared to the study sizes of some
other investigators, we only investigated a relatively
small group of 91 patients. But if the CHK2 1100delC
variant had a major impact for the development of
SCCHN, at least some of the patients should have been
positive for this mutation.
The heterozygous germ line mutation 1100delC of
CHK2 was previously reported to be associated to breast
cancer [18], bladder cancer [23] and prostate cancer
[19-22] and perhaps also to other carcinomas [20,24,25].
Cybulski et al. analyzed multiple kinds of carcinomas for
CHK2 germ line mutations. This study also included
245 laryngeal carcinomas [20]. In this group of patients,
they did not detect any truncating mutation. Therefore,
we were able to confirm these results. Nevertheless, they
found the missense I157T mutation in 4.1% of the cases.
In this study, the incidence of this variant within the
tumor group did not significantly differ from the control
group. Furthermore, Cybulski et al. more recently per-
formed an additional investigation where they analyzed
895 cases of lung cancer, 430 cases of laryngeal cancer
and 6391 controls for the I157T variant. They reported
that the I157T variant appears to be associated with a
decreased risk for developing lung cancer and laryngeal
cancer [30]. In this case, CHK2 alterations may be not
predisposing but protective for head and neck cancer. In
our study, we did not screen our patients for this variant
yet.
U n t i ln o w ,n od a t af o rt w oa d d i t i o n a lm a j o rt u m o r
sites in the head and neck area, hypopharynx and oro-
pharynx, were available for the risk of predisposing
CHK2 mutations. In the present study, we did not find
the CHK2 1100delC variant in any of these patients.
Moreover, patients suffering from multiple tumor
types including squamous cell carcinoma of the head
and neck, showed no CHK2 1100delC variant. This indi-
cates that this particular germ line variation plays no
s i g n i f i c a n tr o l ef o rt h ed e v elopment of cancer of the
upper aerodigestive tract.
However, CHK2 may play a role either in the defense
or the carcinogenesis of these tumors. The ATM-driven
DNA-damage pathway seems to be activated in due to
tobacco smoke, a major carcinogen for the development
of SCCHN, as Tanaka et al recently showed [31].
B e c a u s eC H K 2i sam a j o rt a r g e to fA T M ,as m o k i n g -
dependent-CHK2 activation in SCCHN is likely. Yoon
et al. investigated the expression of phosphorylated
CHK2 (pCHK2) and therefore activated CHK2 in pre-
cancerous lesions of the oral mucosa immunohisto-
chemically. He found that subjects with a positive
pCHK2 staining had a significantly (8.6 fold) higher risk
to develop a squamous cell carcinoma out of this lesion.
He suggested pCHK2 as a putative biomarker for oral
precancerous lesions [32]. However, the authors did not
investigate the occurrence of CHK2 mutations. Serbia et
al. investigated the pCHK2 status of squamous cell car-
cinomas of the esophagus in patients who underwent
neoadjuvant chemotherapy (RTX) immunohistochemi-
cally. They described that pCHK2 positive tumors more
frequently showed clinical regression after RTX [33].
Because esophageal cancer is closely related to the
upper aerodigestive tract, a similar behavior might be
assumed for SCCHN.
Conclusion
The typical 1100delC germ line mutation does not seem
to have a major impact on the risk to develop squamous
cell carcinoma of the head and neck. Since this study is
limited by a relatively low case number, additional stu-
dies including larger groups of patients should be per-
formed. Furthermore, the detection of CHK2 variations
Table 2 The table shows number of patients suffering
from second malignancy.
Secondary malignancy Number of Patients suffering from a
secondary malignancy
Esophagus 6
Lung 3
Basal Cell Carcinoma 4
Bladder 3
Prostate 3
Colon 2
Chronic myeloid
leukemia (CML)
1
Chronic lymphocytic
leukemia (CLL)
1
Melanoma 1
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of the role of CHK2 in the carcinogenesis of SCCHN
remain to be an interesting matter for future
investigations.
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